Psychosocial Issues Influencing Treatment Adherence in Patients on Multidrug Rescue Therapy: Perspectives from Patients and Their Health Care Providers

被引:11
作者
Alfonso, Victoria [1 ,3 ]
Toulson, Adrienne [1 ]
Bermbach, Nicole [1 ]
Erskine, Yvonne [1 ]
Montaner, Julio [1 ,2 ,4 ]
机构
[1] Univ British Columbia, Canadian HIV Trials Network Pacific Reg, Vancouver, BC, Canada
[2] Univ British Columbia, BC Ctr Excellence HIV AIDS, Vancouver, BC, Canada
[3] Univ British Columbia, Dept Educ & Counseling Psychol & Special Educ, Vancouver, BC, Canada
[4] Univ British Columbia, Dept Med, Vancouver, BC, Canada
关键词
HIV-INFECTED INDIVIDUALS; VIROLOGICAL FAILURE;
D O I
10.1089/apc.2008.0115
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Multi-drug rescue therapy (MDRT) is often used for the treatment of highly experienced patients who harbor HIV variants with decreased susceptibility to multiple antiretrovirals. Patients on MDRT typically have limited treatment options, and without treatment, their prognosis can be poor. Yet the decision to go on MDRT is not always straightforward as MDRT can be associated with significant challenges including multiple daily doses, higher pill burden, emerging toxicities, and drug interactions. All of these may compromise adherence, which is often a major reason why patients may need MDRT in the first place. Little is known about how patients and health care providers (HCPs) experience MDRT. This study sought to explore areas of convergence and divergence between patients and HCPs in order to identify gaps in treatment and factors that may impact adherence to MDRT. A qualitative interview method based on grounded theory was used. Twelve patients and seven HCPs completed a 60-minute semistructured interview. Patients were asked about challenges, facilitative aspects of staying on MDRT, the decision to initiate treatment, their role, and the role of HCPs in their health care. HCPs were asked about their experience working with MDRT patients, their role, and the role of the patient. Congruent themes emerged from the two groups: developing a working relationship, treatment factors, information requirements, and readiness for treatment. There were no discrepancies in role perspectives. Patients and HCPs agreed on the need to optimize patients' readiness, willingness, and ability to embark on MDRT to maximize adherence. HCPs assumptions about beginning MDRT based solely on medical indications must be checked and discussed to ensure patients' motivation. In conclusion, adherence to MDRT demands a substantial behavior change, recognized as a major challenge by patients. Allocating the time to make a commitment to treatment can optimize adherence. It is therefore crucial that patients be provided with time to make informed decisions, explore and resolve their willingness and readiness to commit to treatment, and maintain supportive relationships with their HCPs, all of which can optimize adherence to MDRT.
引用
收藏
页码:119 / 126
页数:8
相关论文
共 19 条
[1]   Becoming a " treatment success": What helps and what hinders patients from achieving and sustaining undetectable viral loads [J].
Alfonso, V ;
Geller, J ;
Bermbach, N ;
Drummond, A ;
Montaner, JSG .
AIDS PATIENT CARE AND STDS, 2006, 20 (05) :326-334
[2]  
ALFONSO V, 2006, AIDS PATIENT CARE ST, V20, P16
[3]  
Auerbach C., 2003, Qualitative data. An introduction to Coding and Analysis, DOI DOI 10.5860/CHOICE.41-4324
[4]  
Bandura A., 1977, SOCIAL LEARNING THEO
[5]   Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection [J].
Deeks, SG ;
Barbour, JD ;
Martin, JN ;
Swanson, MS ;
Grant, RM .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (03) :946-953
[6]   Improved survival among HIV-infected individuals following initiation of antiretroviral therapy [J].
Hogg, RS ;
Heath, KV ;
Yip, B ;
Craib, KJP ;
O'Shaughnessy, MV ;
Schechter, MT ;
Montaner, JSG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (06) :450-454
[7]   Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures [J].
Johnson, M ;
Grinsztejn, B ;
Rodriguez, C ;
Coco, J ;
DeJesus, E ;
Lazzarin, A ;
Lichtenstein, K ;
Rightmire, A ;
Sankoh, S ;
Wilber, R .
AIDS, 2005, 19 (07) :685-694
[8]  
Kremer H, 2004, EUR J MED RES, V9, P61
[9]   Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial [J].
Lazzarin, Adriano ;
Campbell, Thomas ;
Clotet, Bonaventura ;
Johnson, Margaret ;
Katlama, Christine ;
Moll, Arend ;
Towner, William ;
Trortier, Benoit ;
Peeters, Monika ;
Vingerhoets, Johan ;
de Smedt, Goedele ;
Baeten, Benny ;
Beets, Greet ;
Sinha, Rekha ;
Woodfall, Brian .
LANCET, 2007, 370 (9581) :39-48
[10]   Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy [J].
Lee, N ;
Hogg, RS ;
Yip, B ;
Harrigan, PR ;
Harris, M ;
O'Shaughnessy, MV ;
Montaner, JSG .
JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (01) :137-141